Where does Herlev Hospital rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Herlev Hospital ranks #40,689 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Herlev Hospital hold?

Herlev Hospital holds 6 US utility patents granted between 2017 and 2023, spanning 10 technology areas.

What is Herlev Hospital's Innovation Score?

Herlev Hospital has an Innovation Score of 48.2 out of 100 (top 17% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Herlev Hospital's patent grant rate increasing or decreasing?

Herlev Hospital's recent grant velocity is +100% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Herlev Hospital's patents?

Herlev Hospital's patents average 17.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Herlev Hospital patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Herlev Hospital

Q: What technology areas does Herlev Hospital focus on?

Herlev Hospital's top technology area is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media) with 4 patents. Grants appear in 10 CPC subclasses total.

USPTO PatentsView assignee record - 6 granted patents across 10 technology areas, recorded in grant years 2017–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Herlev ranks #40,689 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 10 technology areas.

#40,689
of 49,997 US assignees by volume: Top 17%
by Innovation Score (48.2/100): 17.2
avg claims per patent: +100%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R40689 · Foreign Corporation #40,689 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 6 grants
LOWER-Q #40,689/49,997
PHOTO-FINISH Helmholtz-Zentrum…
CPC-FOCUS C12N · 10 areas
INNOV-PAR 48.2/100
CLAIMS-RICH 17.2 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +100% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Helmholtz-Zentrum für Umweltforschung GmbH—UFZ (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Herlev Hospital · this assignee

48
3D Lighting… · lowest

7

What this shows Herlev's Innovation Score is 48.2/100 (top 17% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Herlev's grants concentrate

Herlev Hospital is a focused PatentsView assignee: 10 CPC subclasses with 66.7% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2023 (2 grants) versus a trough of 1 in 2017. By volume, Herlev sits between Helmholtz-Zentrum für Umweltforschung GmbH—UFZ and Hi-Crush Canada Inc..

Herlev's three-year grant acceleration

Herlev Hospital shows 3 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Helmholtz-zentrum…

6
Helmut-schmidt-un…

6
Henri Peteri Behe…

6
Here Enterprise

6
Hero & KG

6
Heshan Jiahaojla…

6
Hexatech

6
Hi-crush Canada

6
Herlev Hospital ◀

6

What this shows Herlev holds 6 patents at rank #40,743, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Herlev

By rank, the assignees closest to #40,743 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Herlev's primary technology class.

Herlev's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

48 Top 17% higher than 83% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Herlev Hospital patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	1	16.7%
2018	1	16.7%
2020	1	16.7%
2022	1	16.7%
2023	2	33.3%

Which technologies does Herlev Hospital patent most?

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 4

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 4

C07K - Peptides 4

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 3

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 3

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 2

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 1

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 1

C12Y - Enzymes 1

Y02A - Technologies FOR Adaptation TO Climate Change 1

Top 10 of 10 technology areas

Where it ranks

Overall rank by patents

#40,689

of 49,997 tracked assignees

Innovation Score

48.2 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Herlev Hospital's patent record in context - here's where to go next.

Herlev Hospital's lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 66.7% of its portfolio - see every assignee active in that class. Explore C12N
Ranked #40,689 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Herlev Hospital against Helmholtz-Zentrum für Umweltforschung GmbH—UFZ, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 48.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.